Fairvalue-Calculator Fairvalue-Calculator
EN DE

Shanghai Rightongene Biotechnology Co (688217) Fair Value & Analysis

Healthcare · CN · Market cap 1.3B CNY

Price¥22.40
Fair Value¥8.88
Upside-60.4%
Quality95/100
Evidence: Medium Range ¥7.07 – ¥10.69

Fair value as of: Jun 24, 2026

Analysis

Shanghai Rightongene Biotechnology Co (688217) currently trades at ¥22.40, while our model-based Fair Value estimate is ¥8.88 — implying the stock looks roughly 60.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Shanghai Rightongene Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products. The company provides gene and antigen testing for patients; and offers treatment plans, such as disease diagnosis, risk assessment, disease classification, targeted drug selection, and efficacy monitoring for for initial screening, follow-up, and re-examination of leukemia patients. It also offers molecular diagnostic kits for genes related to leukemia, lymphoma, solid tumors, and infectious diseases. In addition, it provides third-party medical testing services to various medical institutions, pharmaceutical companies, and individual patients, as well as gene testing research services to research hospitals, pharmaceutical companies, research institutions, and other third-party testing organizations. Shanghai Rightongene Biotechnology Co., Ltd. was founded in 2012 and is based in Shanghai, China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Shanghai Rightongene Biotechnology Co (688217) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥8.88 versus a price of ¥22.40 — about −60% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 688217?
Our 21-model fair value for Shanghai Rightongene Biotechnology Co is ¥8.88 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥22.40.
What is the quality score of 688217?
Shanghai Rightongene Biotechnology Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.